Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MPP Gives 18 December Deadline For Dolutegravir Sublicense Applications

Follows November Licensing Agreement For Four Countries

Executive Summary

The Medicines Patent Pool is giving interested parties until 18 December to submit license applications for the HIV treatment dolutegravir in four middle-income countries, following announcement of the agreement last month.

You may also be interested in...

Shionogi and Medicines Patent Pool Partner To Bring COVID-19 Anti-Viral To 117 Countries

A license agreement between Shionogi and the Medicines Patent Pool aims to widen access to Shionogi’s oral COVID-19 anti-viral ensitrelvir in low to middle-income countries. The investigational drug reduced Omicron-related symptoms in a recent Phase III trial.

MPP Strikes Deal For Long-Acting Injectable HIV Candidate

The University of Washington has agreed to license an in-development HIV treatment to the Medicines Patent Pool, which takes the form of a monthly subcutaneous injection instead of daily oral treatment.

MPP Celebrates First UMIC Dolutegravir Shipments

The Medicines Patent Pool has announced that the first shipments of dolutegravir under a fresh agreement covering upper-middle-income countries have reached Azerbaijan and Belarus.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts